Lobbying

From working for one administration to fending off another: Planned Parenthood's Kevin Griffis

From working for one administration to fending off another: Planned Parenthood's Kevin Griffis

By

Kevin Griffis brought his experience in government and politics to Planned Parenthood at the perfect time, leading the fight to protect birth control coverage under the Trump administration and destigmatizing abortion.

Five things for pharma marketers to know: Tuesday, December 19, 2017

Five things for pharma marketers to know: Tuesday, December 19, 2017

By

Pharma industry spent $57 million on lobbying in 2016; Humana, private equity firms to buy Kindred for $4 billion; price of old glaucoma drug skyrockets

Limits on pharma payments to doctors back on policy menu

Limits on pharma payments to doctors back on policy menu

By

A mini wave of state-level rule-making has thrust the issue of restrictions on pharma payments to medical professionals back into the spotlight.

Five things for pharma marketers to know: Tuesday, April 11, 2017

Five things for pharma marketers to know: Tuesday, April 11, 2017

By

Groups with PhRMA ties warn against drug-pricing proposals; patients learn how to be advocates; the U.K. will not cover Opdivo for head and neck cancer

Five things for pharma marketers to know: Thursday, October 27, 2016

Five things for pharma marketers to know: Thursday, October 27, 2016

By

BIO released a video explaining drug costs; the FDA commits to shorter generic approval process; Kaléo to launch EpiPen competitor

Five things for pharma marketers to know: Friday, July 15, 2016

Five things for pharma marketers to know: Friday, July 15, 2016

By

PhRMA brings on new members, Amgen partners with Daiichi Sankyo on biosimilar commercialization in Japan; Thomson Reuters to sell science unit

Five things for pharma marketers to know: Friday, March 4, 2016

Five things for pharma marketers to know: Friday, March 4, 2016

By

New PhRMA CEO issues policy strategy; study assess patient response to immuno-oncology drugs; Twitter may be an effective way to talk about clinical trials

Five things for pharma marketers to know: Monday, February 8, 2016

Five things for pharma marketers to know: Monday, February 8, 2016

PhRMA and BIO ramp up ad spend for presidential election year; Super Bowl Sunday features three pharma ads; Pfizer solidifies leadership team

Five things for pharma marketers to know: Monday, September 28, 2015

Five things for pharma marketers to know: Monday, September 28, 2015

By

PhRMA hires Ubl as CEO; two drugs report superior results in kidney-cancer trials compared to the standard of care; Novo Nordisk's shares rise on Tresiba approval

Five things for pharma marketers to know: Tuesday, July 21

Five things for pharma marketers to know: Tuesday, July 21

By

Physicians criticize pricing of Orkambi, Vertex's new cystic-fibrosis drug; the EU approves Amgen's PCSK9 inhibitor Repatha; PhRMA boosts lobbying spending in the second quarter

Five things for pharma marketers to know: Friday, April 17

Five things for pharma marketers to know: Friday, April 17

By

The FDA approves generic Copaxone; AstraZeneca's experimental lung-cancer drug demonstrates that it can delay disease progression; PhRMA CEO John Castellani to step down